Evidence map›Paper›PMID 27585851›Full record

ReviewJournal of chemical neuroanatomy2017

Tamoxifen and amphetamine abuse: Are there therapeutic possibilities?

Sarah Mikelman, Natalie Mardirossian, Margaret E Gnegy

Abstract readReview
In one paragraph

Review in Journal of chemical neuroanatomy, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.3field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Sarah MikelmanDepartment of Pharmacology, 2220E MSRB III, 1150 West Medical Center Drive, University of Michigan Medical School, Ann Arbor, MI 28109-5632, United States.
Natalie MardirossianDepartment of Pharmacology, 2220E MSRB III, 1150 West Medical Center Drive, University of Michigan Medical School, Ann Arbor, MI 28109-5632, United States.
Margaret E GnegyDepartment of Pharmacology, 2220E MSRB III, 1150 West Medical Center Drive, University of Michigan Medical School, Ann Arbor, MI 28109-5632, United States. Electronic address: pgnegy@umich.edu.
University of Michigan–Ann Arbor · US

Funding

INTERDEPARTMENTAL TRAINING IN PHARMACOLOGICAL SCIENCEST32GM007767 · NIGMS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI ISOM, LORI L. · 1985 to 2019
$10.2M
PHARMACOLOGY OF DOPAMINE RELEASE BY AMPHETAMINER01DA011697 · NIDA · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI GNEGY, MARGARET E · 2000 to 2016
$5.3M
SUBSTANCE ABUSE INTERDISCIPLINARY TRAINING PROGRAMT32DA007267 · NIDA · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI GNEGY, MARGARET E · 1994 to 2015
$4.5M
NIDA NIH HHS R01 DA011697NIDA NIH HHS T32 DA007267NIGMS NIH HHS T32 GM007767
6 · The paper itself

Abstract

Although best known as a selective estrogen receptor modulator (SERM), tamoxifen is a drug with a wide range of activities. Tamoxifen has demonstrated some efficacy has a therapeutic for bipolar mania and is believed to exert these effects through inhibition of protein kinase C (PKC). As the symptoms of amphetamine treatment in rodents are believed to mimic the symptoms of a manic episode, many of the preclinical studies for this indication have demonstrated that tamoxifen inhibits amphetamine action. The amphetamine-induced increase in extracellular dopamine which gives rise to the 'manic' effects is due to interaction of amphetamine with the dopamine transporter. We and others have demonstrated that PKC reduces amphetamine-induced reverse transport through the dopamine transporter. In this review, we will outline the actions of tamoxifen as a SERM and further detail another known action of tamoxifen-inhibition of PKC. We will summarize the literature showing how tamoxifen affects amphetamine action. Finally, we will present our hypothesis that tamoxifen, or an analog, could be used therapeutically to reduce amphetamine abuse in addition to treating mania.

Indexed as

Amphetamine-Related DisordersAnimalsHumansProtein Kinase CProtein Kinase InhibitorsTamoxifenProtein Kinase CProtein Kinase InhibitorsTamoxifenAmphetamineBipolar maniaDopamineProtein kinase CTamoxifen

Identifiers

PMID27585851
PMCPMC5332479
OpenAlexW2512468347

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.